After the massive COVID outbreak in China, the necessity for general Indian drugs has hiked up in the nation. With the worsening situation, the Chinese are more concerned about the dupes of drugs that are capturing the market.
According to the sources, due to the high quotation of Pfizer, the National Health Security Administration stated that Paxlovid oral drugs would not be counted under basic medical insurance. Pfizer’s Paxlovid is an efficient medicine to treat COVID-19. And with the shortage of this medicine, the necessity for Indian generic versions has drastically hiked up in the e-commerce platforms of China.
The local media reports mentioned Primovir, Paxista, Molnunat, and Molnatris are the four COVID Indian drugs listed and sold on the Chinese e-commerce platforms. They are all approved by Indian authorities and are ideal for emergency use. However, they are not legal in China.
The head of Beijing Memorial Pharmaceutical, He Xiaobing, mentioned while speaking to the media that India can be the only country in the world where China can afford effective COVID medicines that ensure results. However, he further added that the high demand was instigated by groups that produce counterfeit drugs illegally.
Due to the high drug supply costs by several multinational pharmaceutical sharks in China, the healthcare system is at high risk. However, India persuaded China to allow its drugs in the nation so that the citizens could receive medicines at lower costs. This move can also effectively reduce the trade slippage between China and India.
